News Novo Nordisk obesity drug linked to rare cause of sight loss The EMA has become the first regulator to link the use of Novo Nordisk's GLP-1 agonist semaglutide with sight-robbing disorder NAION.
Patients Beyond weight loss: Exploring the impact of weight loss medi... It’s been less than two years since weight loss medications Wegovy and Mounjaro were approved in the UK to treat obesity.
News ACC25: Ozempic shows its value in PAD Novo Nordisk's Ozempic has been shown to improve walking distance in people with diabetes and peripheral artery disease in the STRIDE trial.
Market Access Therapeutic or cosmetic? Patent strategies for dual-use inno... In the pharmaceutical and cosmetic sectors, innovation often stems from discovering new applications for known compounds.
News Compounders cast adrift after semaglutide shortage ends The FDA has said there is no longer a shortage in the US market for Novo Nordisk's GLP-1 agonist semaglutide, ending sales of compounded forms.
News Small study finds GLP-1 drug can curb excess alcohol use Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder.
Digital Chaos & opportunity: Dr Adam Brown unpacks US health policy Dive into our video interview with Dr Adam Brown as he unpacks the chaos and opportunity shaping US health policy.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face